1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow Congenital Hyperinsulinism: new trials by email Literature Review of Congenital Hyperinsulinism trials Research Report on Congenital Hyperinsulinism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) HM15136 - Congenital Hyperinsulinism | Phase 2 | Active not recruiting | Hanmi Pharmaceutical Company Limited | 17 | 2022-05-05 | 2026-08-26 |
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Glucose Metabolism Disorders (1) · Hyperinsulinism (1) · Hypoglycemia (1) · Infant, Newborn, Diseases (1) · Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1) · Pancreatic Diseases (1)
HM15136 (1)
Hanmi Pharmaceutical Company Limited (1)
Germany (1) · Israel (1) · South Korea (1) · United Kingdom (1) · United States (1)